Symbols

ASRT

Assertio Holdings·NASDAQ

--(--)

ASRT fundamentals

ASRT Q4 2025 Earnings

Assertio Holdings (ASRT) released its earnings on Mar 16, 2026: revenue was 13.54M (YoY -57.92%), beat estimates; EPS was -1.86 (YoY -12.73%), beat estimates.

Revenue / YoY

13.54M

-57.92%

EPS / YoY

-1.86

-12.73%

Report date

Mar 16, 2026

ASRT Earnings Call Summary for Q4,2025

Rolvedon Reboot: 2026 guidance reflects return to normalized sales post-label transition, with potential to exceed $100M annually.
Oncology Expansion: Shifting focus to oncology therapeutics, with modest sales force expansion (~10-20%) to support new product launches.
Financial Resilience: $63.4M cash balance and 2026 EBITDA guidance of $28M-$40M demonstrate strong financial footing for growth.
Strategic Shift: Moving away from high-cost specialty product acquisitions, focusing on disciplined oncology BD opportunities.

Earnings

EPS

Revenue

Revenue & Expenses

ASRT has released its 2025 Q4 earnings report, with revenue of 13.54M, reflecting a YoY change of -57.92%, and net profit of -11.93M, showing a YoY change of -13.85%. The Sankey diagram below clearly presents ASRT's revenue sources and cost distribution.

Key Indicators

Assertio Holdings (ASRT) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Assertio Holdings (ASRT)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Assertio Holdings (ASRT)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Assertio Holdings (ASRT)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown